Journal
MOLECULAR THERAPY
Volume 30, Issue 1, Pages 468-484Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2021.06.009
Keywords
-
Categories
Funding
- NIH/NIDCR [DE027551, DE022567]
- NIH/National Cancer Institute - Cancer Center Shared Resource: Experimental Irradiation [P30CA046592]
- HNSPORE [P50CA097248]
Ask authors/readers for more resources
Radiation therapy, a common treatment for head and neck cancer, is not always effective due to the development of resistance. This study reveals that EGFR-mediated phosphorylation of TRIP13 at Y56 is a vital mechanism for radiation resistance and proposes TRIP13-pY56 as a predictive indicator for the response to radiation or cetuximab, and as a potential therapeutic target.
Radiation therapy, a mainstay of treatment for head and neck cancer, is not always curative due to the development of treatment resistance; additionally, multi-institutional trials have questioned the efficacy of concurrent radiation with cetuximab, the epidermal growth factor receptor (EGFR) inhibitor. We unraveled a mechanism for radiation resistance; that is, radiation induces EGFR, which phosphorylates TRIP13 (thyroid hormone receptor interactor 13) on tyrosine 56. Phosphorylated (phospho-)TRIP13 promotes non-homologous end joining (NHEJ) repair to induce radiation resistance. NHEJ is the main repair pathway for radiation-induced DNA damage. Tumors expressing high TRIP13 do not respond to radiation but are sensitive to cetuximab or cetuximab combined with radiation. Suppression of phosphorylation of TRIP13 at Y56 abrogates these effects. These findings show that EGFR-mediated phosphorylation of TRIP13 at Y56 is a vital mechanism of radiation resistance. Notably, TRIP13-pY56 could be used to predict the response to radiation or cetuximab and could be explored as an actionable target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available